Our Medicines
Below is a list of the medicines that AstraZeneca currently markets in Canada including product monographs and consumer information. Product Monographs for approved, but not marketed products are not provided to the public by AstraZeneca Canada as they may not reflect the Product’s most current information. If you have questions about an approved, but not marketed product, please contact AstraZeneca Medical Information. Canadian regulations limit the scope of information we are permitted to give on prescription drugs via the internet or other means. Please consult a qualified health professional for more detailed information.
Please contact AstraZeneca Medical Information with any comments or inquiries.
Please refer to the Health Canada Web site for Health Canada Advisories and Warnings.
A - E
PrARIMIDEX® |
Product Monograph
|
AstraZeneca COVID-19 Vaccine |
Product Monograph
Advisories Health Product Risk Communication - COVAX-Labelled Supply 2021-02-26 Health Product Risk Communication - Safety Update 2021-03-24 Health Product Risk Communication - US-Labelled Supply 2021-03-31
|
PrATACAND® |
Product Monograph
|
PrATACAND® Plus |
Product Monograph
|
PrBRICANYL® TURBUHALER® |
Product Monograph
|
PrBRILINTA® |
Product Monograph
|
PrBYDUREON®
|
Product Monograph
|
PrBYETTA®
|
|
PrCALQUENCE® |
Product Monograph
|
PrCASODEX® |
Product Monograph
|
PrCRESTOR® |
Product Monograph
Advisories
|
PrDAXAS®
|
Product Monograph
|
PrDUAKLIR GENUAIR® |
Product Monograph
|
PrENHERTUTM
|
Product Monograph
|
F - J
PrFASENRA® |
Product Monograph
|
PrFASLODEX® |
Product Monograph
Advisories
|
FLUMIST® QUADRIVALENT |
Product Monograph
|
PrFORXIGA® |
Product Monograph
Advisories Dear Healthcare Professional Letter 2015-07-10
|
PrIMFINZI® |
Product Monograph
|
PrIRESSA® |
Product Monograph
Advisories
|
K - O
PrKOMBOGLYZE® |
Product Monograph
|
PrLOKELMATM |
Product Monograph
|
PrLYNPARZA® Tablets |
Product Monograph
Advisories
|
PrNEXIUM® |
Product Monograph
|
PrNOLVADEX®-D |
Product Monograph
|
PrONGLYZA® |
Product Monograph
|
PrOXEZE® TURBUHALER® |
Product Monograph
|
P - T
PrPLENDIL® |
Product Monograph
|
PrPULMICORT® NEBUAMP® |
Product Monograph
|
PrPULMICORT® TURBUHALER® |
Product Monograph
Advisories
|
PrSEROQUEL XR® |
Product Monograph
|
PrSEROQUEL® |
Product Monograph
|
PrSYMBICORT® TURBUHALER® |
Product Monograph
|
PrTAGRISSO® |
|
PrTENORMIN® |
|
PrTUDORZA® GENUAIR® |
U - Z
PrVIMOVO® |
Product Monograph
|
PrXIGDUO® |
Product Monograph
Advisories
|
PrZESTORETIC® |
Product Monograph
|
PrZESTRIL® |
Product Monograph
|
PrZOMIG® and ZOMIG RAPIMELT® |
|
PrZOMIG® Nasal Spray |
|
PrZOMIG®, ZOMIG RAPIMELT® and ZOMIG® Nasal Spray |
|
AstraZeneca Canada is committed to ensuring the safe and effective collection and disposal of expired and/or unused health products. We are a member of the Health Products Stewardship Association.
Don't throw them out, visit www.healthsteward.ca
Product Inquiries & Adverse Event Reporting
We are committed to patient safety. If you have any questions or experience any side effects while taking an AstraZeneca medication, please contact us as noted below.
By Phone: 1-800-668-6000 (English), 1-800-461-3787 (French)
Monday - Friday 8 a.m. - 5 p.m. (EST), excluding holidays
By email: medinfo.Canada@astrazeneca.com
Online: https://aereporting.astrazeneca.com/home.html
Your information will be documented in our AstraZeneca database. We are committed to protecting and controlling the collection, use and disclosure of personal information of individuals that interact with us in accordance with applicable Canadian privacy laws. For further information, please review our Privacy Policy. If you have specific medical questions, please contact your healthcare professional.